Catalent Expands Biologics Capabilities

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-12-02-2015
Volume 11
Issue 12

Expansions at Catalent’s Kansas City, MO, and Madison, WI facilities made in response to industry demand.

Catalent Pharma Solutions has announced the multi-site expansion of its analytical and process development capabilities for biologics including include an expansion of bioassay and protein characterization capabilities at its Kansas City, MO, facility, and additional integrated analytical capabilities at its Madison, WI, bio-manufacturing facility.

The investments were made in response to increased industry demand for large molecule analytical services, regulatory expectations around NBEs, and additional characterization requirements for biosimilars, the company reported in a Nov. 20, 2015 statement. The investment in Kansas City enables the facility to offer dual and complementary options for kinetic and quantitative binding assays for characterization and GMP testing.

The expansion at the Madison site will be operational by January 2016. The company has expanded process development capability at the Madison site, including integration of the Ambr 15 microbioreactor system into its cell line and upstream development.

Source: Catalent Pharma Solutions

 

 

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Related Content